Preclinical Research Highlights mGlu7 Modulation in Sleep Regulation
A newly published study shows that ADX71743, a selective mGlu7 inhibitor, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models.
A newly published study shows that ADX71743, a selective mGlu7 inhibitor, significantly modulates sleep-wake regulation and stress-related neurochemistry in animal models.
A post hoc analysis of the SELECT trial suggests that semaglutide 2.4 mg is associated with a significantly lower incidence of obstructive sleep apnea in adults with overweight or obesity and established cardiovascular disease. While these findings are promising, Novo Nordisk notes that semaglutide is not currently approved to treat obstructive sleep apnea and further research is required.
New referral pathways and consumer awareness may bring millions into sleep medicine. But if clinicians ignore physiologic heterogeneity and narrative context, more testing could still produce fragmented care.
A study of 28 million days of health data reveals that fewer than 13% of individuals consistently meet both sleep and physical activity guidelines, suggesting that high-quality sleep is a primary driver of next-day movement. The findings indicate that prioritizing sleep may be a more effective strategy for increasing daily activity than the reverse.
A mastery-based cognitive-behavioral model centers on "nightmare efficacy" to help clinicians create personalized treatment plans for youth.
The American College of Lifestyle Medicine released a toolkit providing guidance and patient education for pairing obesity medications like GLP-1s with lifestyle care.
Authored by Danielle Drees, the upcoming release from University of Minnesota Press examines sleep and sleeplessness as embodiments of core feminist concerns.